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Abstract 
A pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) is a signature of favorable prognosis in 
breast cancer. The aim of this study was to assess the accuracy of magnetic resonance imaging (MRI) in predicting the 
pCR after NAC. 265 women with stage II or III breast cancer who underwent surgery after NAC were retrospectively 
investigated for MRI findings before and after the NAC. Correlation of pCR with an “imaging complete response” (iCR), 
defined as no detectable tumor on all serial images with dynamic contrast-enhanced T1-weighted imaging, was 
evaluated with respect to each tumor subtype. Of 265 cases, 44 (16.6 %) and 24 (9.1 %) were diagnosed as iCR and 
pCR, respectively. Nineteen of the 44 iCR cases (43.2 %) were assessed as pCR, and 216 (97.7 %) of the 221 non-iCR 
cases were assessed as non-pCR. The accuracy (ACC), the pCR predictive value (PPV) and the non-pCR predictive 
value (NPV) were 88.7, 43.2, and 97.7 %, respectively. When assessed according to each tumor subtype, the ACC, PPV 
and NPV were 93.2, 21.4 and 100 % for luminal subtype, 70.8, 0 and 89.5 % for luminal/HER2 subtype, 75, 57.1 and 
88.8 % for HER2-enriched subtype, and 90.9, 72.7 and 97 % for triple-negative subtype, respectively. MRI is a valuable 
modality for predicting pCR of breast cancer after NAC treatment. However, its accuracy varies greatly in different 
breast cancer subtypes. Whereas MRI closely predicts pCR in the triple-negative subtype, iCR in the luminal subtype is 
often an over-estimation. On the other hand, residual lesions identified by MRI are reliable markers of non-pCR for the 
luminal subtype.
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Background
Neoadjuvant chemotherapy (NAC) is one of the recom-
mended treatments for operable invasive breast cancer. 
Published clinical trials have shown that breast cancer 
patients with pathological complete responses (pCR) 
to NAC have significantly better prognosis than those 
without pCR (Wolmark et  al. 2001; Van der Hage et  al. 
2001; Bear et  al. 2006). Therefore, pCR is an important 
prognostic factor in breast cancer treated with NAC. Von 
Minckwitz et  al. reported that the prognostic impact of 
pCR varied among tumor subtypes classified by their 
expression of hormone receptors (HRs) and human 
epidermal growth factor receptor 2 (ErbB2, hereinaf-
ter called HER2). Although pCR significantly correlates 
with favorable prognosis in triple-negative and HER2-
enriched subtypes, it fails to predict the prognosis of 
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luminal and luminal/HER2 subtypes (von Minckwitz 
et al. 2012).
Monitoring therapeutic responses to NAC, including 
early detection of progressive disease, is of pivotal impor-
tance in clinical practice. Physical examination, mam-
mography, ultrasonography and magnetic resonance 
imaging (MRI) are widely used for the assessment of 
therapeutic effect.
MRI is a useful device to assess the size and extent of 
lesions in breast cancer. The size of the invasive compo-
nent of the tumor estimated by MRI closely correlates 
with that determined pathologically. MRI is also capable 
of detecting small residual cancer nests after NAC (Par-
tridge et al. 2002). Londero et al. reported that MRI could 
assess responses to NAC better than physical examina-
tion, mammography or ultrasonography (Londero et  al. 
2004). Ideally, if MRI were able to perfectly distinguish 
pCR from non-pCR, additional mastectomy would be 
avoided. The present study was conducted to determine 
the accuracy of MRI estimation of tumor regression 
in predicting pCR. We propose that assessments with 




A total of 2767 cases with primary breast cancer under-
went surgery from January 2005 to December 2007 at the 
Cancer Institute Hospital of the Japanese Foundation for 
Cancer Research. During this period 402 patients were 
treated with NAC. Of these, 265 with stage II–III invasive 
breast cancer, no special type, where MRI had been per-
formed before and after chemotherapy, were included in 
this study. In our hospital, breast cancer patients usually 
undergo MRI before treatment. MRI after NAC is per-
formed preferentially in patients, where indications for 
breast-conserving therapy need to be assessed. We retro-
spectively investigated the relationship between pCR and 
imaging complete response (iCR) evaluated by MRI.
Chemotherapy regimen of NAC
Standard anticancer drugs including anthracycline and/
or taxane were administered to all patients as NAC. Sixty 
five patients received an anthracycline-based combina-
tion regimen, 22 received only taxane and the remaining 
178 were treated with the anthracycline-based combina-
tion regimen followed by taxane. The former involved 
4–6 cycles of CAF (cyclophosphamide 500 mg/m2, adri-
amycin 50  mg/m2, fluorouracil 500  mg/m2, q3w), AC 
(adriamycin 60  mg/m2, cyclophosphamide 600  mg/m2, 
q3w), and CEF (cyclophosphamide 500  mg/m2, epiru-
bicin 100 mg/m2, fluorouracil 500 mg/m2, q3w) therapy. 
The taxane regimens were 12 cycles of weekly paclitaxel 
at a dose of 80 mg/m2 or 4 cycles of tri-weekly docetaxel 
at a dose of 75 mg/m2. In Japan, postoperative adminis-
tration of trastuzumab was approved for health insur-
ance coverage in 2008. In the present study, none of the 
patients were administered trastuzumab preoperatively.
MRI
MRI examinations were performed using a 1.5T MRI 
unit (Signa HD, GE Health Care, Milwaukee, USA) and 
a commercially-available dedicated four-channel breast 
array coil. Patients underwent MRI in the prone position. 
Our imaging protocol included a localizing sequence fol-
lowed by unilateral fast spin-echo T2-weighted coronal 
imaging (TR/TE, 4800/85 ms; echo train length 16, and 
matrix 384 × 224) with fat suppression by chemical shift-
selective imaging sequences. Other parameters were as 
follows: field of view, 260  mm; section thickness, 3  mm 
and interslice gap, 0 mm. This examination was followed 
by combined dynamic contrast-enhanced unilateral coro-
nal breast imaging. An enhanced T1-weighted exami-
nation 3D gradient echo sequence with fat suppression 
by spectral inversion recovery was performed before 
and after contrast material injection. The image param-
eters were as follows: TR/TE/FA, 3.6  ms/1.0  ms/15°; 
FOV, 26 × 26 cm; matrix, 320 × 240; section thickness, 
3.0 mm; interslice gap, 0 mm and acquisition time, 60 s. 
A dynamic study in the coronal plane was performed 
before and 60, 120, 180 and 240 s after starting intrave-
nous injection of 0.2  mmol/kg of gadodiamide hydrate 
(Omniscan®, Daiichi-Sankyo, Tokyo, Japan) at a rate of 
3  mL/s, followed by a 20  mL saline flush at the rate of 
3 mL/s.
iCR was defined as no enhanced tumor visible on any 
serial images of dynamic contrast-enhanced T1-weighted 
images. If dynamic MRI showed any amount of enhanced 
area, the case was diagnosed as non-iCR in this study. 
Non-iCR included “partial response”, “stable disease” and 
“progressive disease” according to the Response Evalua-
tion Criteria in Solid Tumors (RECIST) Guidelines.
Pathological examination of surgical specimens
Detailed evaluation of surgical specimens was carried 
out. Partial mastectomy specimens were cut into 5  mm 
thick serial sections and formalin-fixed paraffin blocks 
were made from the all sections. The all blocks cut into 
thin slices and were examined microscopically. In total 
mastectomy specimens, the location of the tumor bed 
was firstly identified from the clinical information and 
gross observation of the cut surfaces. Next, many tissue 
blocks broadly distributed around the tumor bed were 
sampled and microscopically examined.
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pCR was defined as no invasive cancer cells in any 
slices of the resected breast specimen. pCR was allowed 
for in situ carcinoma and for positive lymph nodes.
Subtype classification by HR and HER2 status
Tumors were classified into four subtypes based on the 
two HRs, the estrogen receptor (ER) and the progester-
one receptor (PgR), and HER2. The status of these bio-
markers was estimated using biopsy samples obtained 
before chemotherapy. Immunohistochemical staining for 
ER and PgR was performed using antibody clone 1D5 for 
ER and for clone PgR636 for PgR (both Dako Japan Inc., 
Tokyo). Positive reactions for ER and PgR were defined 
as nuclear staining in ≥10 % of cancer cells, and negative 
reactions were defined as staining in <10 %. HR-positivity 
was defined as positivity for ER and/or PgR. Immuno-
histochemical staining for HER2 was performed using 
the Hercep Test (Dako Japan Inc.). Expression of HER2 
protein was classified into 4 strata, i.e., 0, 1+, 2+ and 
3+. In the 2+ cases, HER2 genetic testing by fluores-
cence in  situ hybridization (FISH) was performed using 
the PathVysion HER2-DNA Probe Kit (Abbott Molecular 
Inc., Des Plaines, USA). Both protein and genetic status 
were estimated based on the guidelines for HER2 testing 
in breast cancer, as recommended by the American Soci-
ety of Clinical Oncology/College of American Patholo-
gists (Wolff et al. 2013). HER2 positivity was defined as 
HER2 protein 3+ or HER2 gene amplification. Subtype 
definitions were as follows: luminal subtype, HR-positive 
and HER2-negative; luminal/HER2 subtype, HR-positive 
and HER2-positive; HER2-enriched subtype, HR-nega-
tive and HER2-positive; and triple-negative subtype, HR-
negative and HER2-negative.
Statistical analysis
Statistical analysis was performed using SPSS statistics 
Ver17.0 (IBM Japan Inc., Tokyo, Japan). The Fisher’s exact 
test was used to compare iCR and pCR. P  <  0.05 was 
taken to indicate statistical significance in all instances.
Ethical issues
Informed consent for the use of specimens was obtained 
preoperatively from all patients participating in this 
study, which was approved by the Institutional Review 




All patients studied were female with a mean age at the 
beginning of treatment of 49.9  years (range 25–78). 
Tumors were at Stage II (172 cases) or Stage III (93 cases) 
with a tumor size >2  cm (T2, 172 cases, 64.9  %; T3, 38 
cases, 14.3  %; T4, 38 cases, 14.3  %) or/and positive for 
lymph node metastasis (199 cases, 75  %). The latter 
included seventeen cases of T1 with positive lymph node 
metastasis (6.4 %). Total mastectomy was performed on 
165 patients (62.3  %) with the remaining 100 undergo-
ing partial mastectomy (37.7 %). ER, PgR and HER2 were 
positive in 70.6, 46.4 and 21.1  % of cases, respectively. 
Data on at least one of the biomarkers were missing for 
4 patients’ biopsies from other hospitals. Regarding sub-
type criteria combining HR and HER2, 161 cases were 
classified as luminal subtype (60.8  %), 24 were luminal/
HER2 (9.1 %), 32 were HER2-enriched (12.1 %) and the 
remaining 44 were triple-negative (16.6 %).
Comparison of iCR with pCR in the whole patient cohort
Of the total of 265 patients, 44 were diagnosed as iCR 
by MRI (16.6  %) and 24 as pCR (9.1  %). Of the 44 iCR 
patients, 19 were also diagnosed as pCR (43.2 %) and the 
remaining 25 as non-pCR (56.8  %). Of the 221 patients 
who were non-iCR, 216 were also diagnosed as non-
pCR (97.7 %) but the remaining 5 were diagnosed as pCR 
(2.3 %). Thus, iCR was significantly correlated with pCR 
in the whole cohort (P < 0.001, Table 1).
Sensitivity, specificity, accuracy (ACC), pCR predictive 
value (PPV) and non-pCR predictive value (NPV) were 
estimated as 79.2, 89.6, 88.7, 43.2 and 97.7 %, respectively 
(Table 2).
Comparison of iCR and pCR with respect to subtype 
classification
Proportions of patients with iCR in each subtype were 
as follows: 8.7 % (14/161) luminal, 20.8 % (5/24) luminal/
Table 1 Comparison between iCR and pCR
pCR pathological complete response, iCR imaging complete response
iCR non-iCR P value
All patients (n = 265)
 pCR 19 5 <0.001
 non-pCR 25 216
Luminal subtype (n = 161)
 pCR 3 0 0.001
 non-pCR 11 147
Luminal/HER2 subtype (n = 24)
 pCR 0 2 1.000
 non-pCR 5 17
HER2-enriched subtype (n = 32)
 pCR 8 2 0.008
 non-pCR 6 16
Triple-negative subtype (n = 44)
 pCR 8 1 <0.001
 non-pCR 3 32
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HER2, 43.8 % (14/32) HER2-enriched and 25.0 % (11/44) 
triple-negative. In contrast, proportions of patients with 
pCR in each subtype were 1.9 % (3/161) for luminal, 8.3 % 
(2/24) luminal/HER2, 31.3 % (10/32) HER2-enriched and 
20.5 % (9/44) triple-negative. Statistically significant cor-
relations between iCR and pCR were present for luminal 
(P = 0.001), HER2-enriched (P = 0.008) and triple-nega-
tive (P < 0.001) subtypes, but not for the luminal/HER2 
subtype (P = 1.000) (Table 1).
The sensitivity, specificity, ACC, PPV and NPV for 
correlations of iCR with pCR with respect to each sub-
type are shown in Table 2. For the luminal subtype, the 
NPV was 100  %, with a perfect concordance for all 147 
patients with non-iCR pathologically diagnosed as non-
pCR. However, only 3 of 14 iCR cases were indeed pCR, 
indicating a low PPV of 21.4 %. Although the sensitivity 
(100 %), specificity (93.0 %) and the ACC (93.2 %) were 
very high, these rely on the high NPV and small propor-
tion of pCR. In contrast to luminal subtype, the PPV for 
the triple-negative subtype was 72.7 %, the highest score 
among all the subtypes, with 8 of 11 iCR cases being pCR. 
Sensitivity (88.9  %), specificity (91.4  %), ACC (90.9  %) 
and NPV (97  %) were also significantly higher for the 
triple-negative subtype, suggesting that MRI is a valuable 
modality to predict pCR for this subtype. For the HER2-
enriched subtype, sensitivity (80.0 %), specificity (72.7 %), 
ACC (75.0 %), PPV (57.1 %) and NPV (88.9 %) were rea-
sonably high. On the other hand, sensitivity (0 %), speci-
ficity (77.3 %), ACC (70.8 %), PPV (0 %) and NPV (89.5 %) 
were relatively low for the luminal/HER2 subtype.
An example of a case diagnosed as both iCR and pCR
Figure  1 shows the MR images and pathological find-
ings of a 60-year-old patient with invasive breast can-
cer (T2N1M0, stage II) concordantly diagnosed as iCR 
and pCR after NAC. The tumor was 3.5 cm in diameter 
before NAC and MRI demonstrated a solid enhanced 
mass with a micro-lobulated margin (Fig.  1a). A core 
needle biopsy specimen of the tumor showed an invasive 
ductal carcinoma with solid growth pattern and high-
grade cancer cells (Fig.  1b, c). Immunohistochemical 
analyses indicated that the tumor was HR-negative and 
HER2-positive, i.e., the HER2-enriched subtype. After 
NAC, no enhanced area was detectable by MRI in either 
early or late phases, indicating an iCR tumor response 
(Fig.  1d). Pathological assessment of the surgical speci-
men showed only fibrous granulation tissue in the tumor 
bed without any residual invasive cancer cells, indicating 
a pCR (Fig. 1e, f ). A few in situ cancer cells were observed 
(Fig. 1f ).
Analysis of cases diagnosed as iCR but non-pCR
Twenty five of 44 cases diagnosed as iCR by MRI were 
assessed by pathology as non-pCR (56.8  %). When 
assessed for subtype distribution, proportions of non-
pCR in iCR cases were 78.6  % (11/14) for the luminal 
subtype, 100  % (5/5) for the luminal/HER2 subtype, 
42.6  % (6/14) for the HER2-enriched subtype and 
27.3  % (3/11) for the triple-negative subtype (Table  1). 
When non-pCR but iCR cases were assessed for the 
histological therapeutic effect according to the criteria 
recommended by the Japanese Breast Cancer Society 
(Kurosumi et  al. 2008), 3 of 11 cases of luminal sub-
type were “slightly responsive” with the other 8 cases 
being “moderately responsive”, whereas only one each of 
the luminal/HER2, HER2-enriched and triple-negative 
subtypes were “slightly responsive”. On the basis of the 
nuclear grade of cancer cells, 6 of 11 cases of the lumi-
nal subtype were classified as low grade. The 3 “slightly 
responsive” patients with luminal subtype all showed 
a low nuclear grade. Figure  2 depicts the MR images 
and pathological findings of a 60-year-old patient with 
T1N1M0 stage II invasive breast cancer that was dis-
cordantly diagnosed as iCR but non-pCR after NAC. 
The tumor was 2.1  cm in diameter before NAC, and 
MRI demonstrated a solid enhanced polygonal mass 
(Fig.  2a). Here, a core needle biopsy specimen of the 
tumor showed an invasive ductal carcinoma with scir-
rhous invasion of low-grade cancer cells (Fig. 2b, c). The 
tumor was HR-positive and HER2-negative, the luminal 
subtype. After NAC, an enhanced area was no longer 
detected by MRI in either early or late phases; thus, the 
tumor response was iCR (Fig. 2d). Pathological analysis 
of the surgical specimen, however, revealed scattered 
small invasive nests of residual cancer cells in the tumor 
bed, indicating a non-pCR (Fig. 2e, f ).
Table 2 Sensitivity, specificity, ACC, PPV and NPV in each tumor subtype
ACC accuracy, PPV positive predictive value, NPV negative predictive value
Sensitivity (%) Specificity (%) ACC (%) PPV (%) NPV (%)
All patients (n = 265) 79.2 89.6 88.7 43.2 97.7
Luminal subtype (n = 161) 100 93.0 93.2 21.4 100
Luminal/HER2 subtype (n = 24) 0 77.3 70.8 0 89.5
HER2-enriched subtype (n = 32) 80.0 72.7 75.0 57.1 88.9
Triple-negative subtype (n = 44) 88.9 91.4 90.9 72.7 97.0
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Fig. 1 MR images and pathological findings of a case with iCR and pCR. a, d MR images of a HER2-enriched breast cancer before (a) and after (d) 
NAC. No enhancement was detected by MRI after NAC. c–f Histological findings of the pathological specimens before (c, d) and after (e, f) NAC. 
Hematoxylin and eosin staining at low (×40, c, e) and high (×100, d, f) magnification. No residual invasive cancer cells were identified. Fibrotic and 
granular changes are observed instead
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Fig. 2 MR images and pathological findings of a case with iCR but non-pCR. a, d MR images of a luminal type breast cancer before (a) and after (d) 
NAC. After NAC, tumor was no longer enhanced, yielding an iCR. c–f Histological findings of the pathological specimens before (c, d) and after (e, 
f) NAC. Hematoxylin and eosin staining at low (×40, c, e) and high (×100, d, f) magnification. Cancer cells before NAC showed low nuclear grade. 
Pathology of the surgical specimen showed scattered small invasive nests of residual cancer cells in the tumor bed. Histological therapeutic effect 
was estimated as a “slight response”
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Fig. 3 MR images and pathological findings of a case with non-iCR but pCR. a, d MR images of a HER2-enriched breast cancer before (a) and after 
(d) NAC. After NAC, no mass was detected but revealed scattered dendritic enhancement which predicted non-iCR. c–f Histological findings of 
the pathological specimens before (c, d) and after (e, f) NAC. Hematoxylin and eosin staining at low (×40, c, e) and high (×100, d, f) magnification. 
Pathology after surgery shows fibrous granulation tissue without residual cancer cells, regarded as a pCR
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Analysis of cases diagnosed as non-iCR but with pCR
Reciprocally, we found that MRI discordantly diagnosed 
five cases of pCR as non-iCR. Fibrous granulation tissue 
that may have caused the misdiagnosis was observed in 
all five cases. Figure 3 shows the MR images and patho-
logical findings of a 50-year-old patient with an invasive 
breast cancer (T4bN3M0, stage III) that was discordantly 
diagnosed as non-iCR but pCR after NAC. The tumor 
was 4  cm in diameter before NAC and MRI revealed a 
solid enhanced mass with cord-like enhancements in the 
lateral and the nipple side of the mass, suggesting an inva-
sive carcinoma with ductal spread (Fig. 3a). A core needle 
biopsy specimen of the tumor showed an invasive ductal 
carcinoma with solid-tubular structure of intermedi-
ate grade cancer cells (Fig. 3b, c). Immunohistochemical 
analyses indicated that the tumor was HR-negative and 
HER2-positive, the HER2-enriched subtype. MRI after 
NAC showed a mass 5  mm in diameter with scattered 
dendritic enhancement in the later phase, signifying 
non-iCR (Fig.  3d). Pathology, however, showed fibrous 
granulation tissue in the center of the surgical specimen 
without residual cancer cells, indicating a pCR (Fig. 3e, f ). 
The fibrous granulation tissue contained numerous small 
vessels and inflammatory cells (Fig. 3f ).
Discussion
In the present study, we investigated the accuracy of MRI 
for predicting pCR of breast cancer after NAC, espe-
cially focusing on its value in respect to each tumor sub-
type. When all cases were considered together, the iCR 
results were found to correlate significantly with pCR. 
These results are consistent with previously reported data 
(Straver et al. 2010; Yuan et al. 2010; McGuire et al. 2011; 
Hayashi et al. 2013). However, the degree of accuracy was 
found to differ markedly according to the tumor subtype 
considered. For the luminal subtype, whereas NPV was 
high, PPV was considerably low. This suggests that rem-
nant lesions identified by MRI are reliable markers of 
non-pCR for the luminal subtype, i.e., MRI is effective for 
predicting non-pCR after NAC; however, iCR diagnosed 
by MRI in the luminal subtype is mostly an over-estima-
tion. On the other hand, MRI accurately predicted pCR 
in the triple-negative subtype with a high degree of sen-
sitivity, specificity, ACC, PPV and NPV compared to the 
other subtypes. These results are consistent with previous 
reports (Straver et al. 2010; Yuan et al. 2010; McGuire et al. 
2011; Hayashi et al. 2013; Chen et al. 2014; De Los et al. 
2011; Loo et al. 2011). Although a larger cohort would be 
required before drawing definitive conclusions, especially 
for the luminal and luminal/HER2 subtypes, which com-
prised only a small number of pCR cases, our data suggest 
that the overall accuracy of prediction by MRI for pCR 
can be enhanced by subgroup analyses. The relationship 
between the accuracy of MRI and subtype classification 
may be caused by the following points. The pCR rate of 
the triple-negative subtype was higher than the luminal 
subtype. MRI for predicting pCR is generally more accu-
rate in tumors that have a better response. It is also known 
that the ER-negative tumor have higher contrast uptake on 
MRI after NAC than ER-positive tumor (Chen et al. 2014). 
In the triple-negative subtype, the high contrast uptake 
may result the high accuracy of MRI diagnosis.
In the present study, cases with results discordant 
between iCR and pCR were carefully analyzed for patho-
logical findings. MRI diagnosed 25 cases of non-pCR as 
iCR. There likely to be at least two different reasons for 
this misdiagnosis. For HER2-enriched and triple-neg-
ative subtypes, the small volume of the residual cancer 
cells, often present with a scattered distribution pattern, 
could be responsible for their evading detection by MRI. 
In the cases of luminal subtype, MRI may fail to detect 
tumors with low nuclear grade despite a relatively large 
tumor size. The proportion of non-pCR in the iCR group 
was disturbingly high in this subtype, despite the major-
ity of the cases having relatively large tumors and show-
ing slight therapeutic responses. These cases all had low 
nuclear grade tumors. Reciprocally, MRI diagnosed five 
cases of pCR as non-iCR. These five shared the com-
mon findings of fibrosis and granulation occupying the 
tumor bed of the surgical specimen. Because the fibrous 
granulation tissue contained numerous small vessels 
and inflammatory cells, it is most likely that these NAC-
responsive structures mimicked the remnant tumor in 
the MRI findings (Woodhams et al. 2010).
In conclusion, subgroup analysis with respect to each 
tumor subtype enhances the accuracy of MRI for predict-
ing pCR after NAC treatment of breast cancer. It is an 
especially valuable technique for the prediction of pCR 
in triple-negative breast cancer. Now, we are planning a 
study which confirms this result with lager patients.
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